Daniel Starks Biography and Net Worth

Director of Abbott Laboratories


Daniel J. Starks serves as Independent Director of the Company. Mr. Starks served as the Chairman, President and Chief Executive Officer of St. Jude Medical, Inc. from 2004 until his retirement in January 2016, after which he served as its Executive Chairman of the Board until January 2017, when Abbott completed the acquisition of St. Jude Medical. Mr. Starks also served as President and Chief Operating Officer of St. Jude Medical from 2001 to 2004 and as its President and CEO, Cardiac Rhythm Management Business from 1997 to 2001. Having served as St. Jude Medical's Executive Chairman and its Chairman, President and Chief Executive Officer, and having joined St. Jude Medical in 1996, Mr. Starks contributes not only comprehensive and critical knowledge of St. Jude Medical's operations, but also extensive business and management experience operating a global public company in a highly regulated industry.

What is Daniel J. Starks' net worth?

The estimated net worth of Daniel J. Starks is at least $768.77 million as of October 26th, 2023. Mr. Starks owns 6,725,316 shares of Abbott Laboratories stock worth more than $768,770,872 as of December 23rd. This net worth estimate does not reflect any other investments that Mr. Starks may own. Learn More about Daniel J. Starks' net worth.

How do I contact Daniel J. Starks?

The corporate mailing address for Mr. Starks and other Abbott Laboratories executives is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. Abbott Laboratories can also be reached via phone at (224) 667-6100. Learn More on Daniel J. Starks' contact information.

Has Daniel J. Starks been buying or selling shares of Abbott Laboratories?

Daniel J. Starks has not been actively trading shares of Abbott Laboratories over the course of the past ninety days. Most recently, Daniel J. Starks sold 50,000 shares of the business's stock in a transaction on Thursday, October 26th. The shares were sold at an average price of $94.05, for a transaction totalling $4,702,500.00. Following the completion of the sale, the director now directly owns 6,725,316 shares of the company's stock, valued at $632,515,969.80. Learn More on Daniel J. Starks' trading history.

Who are Abbott Laboratories' active insiders?

Abbott Laboratories' insider roster includes Hubert Allen (Executive Vice President, General Counsel and Secretary), Roxanne Austin (Director), Roger Bird (SVP), Brian Blaser (Insider), Philip Boudreau (VP), Sharon Bracken (Insider), John Capek (EVP), Jaime Contreras (SVP), Michael Dale (SVP), Lisa Earnhardt (EVP), Robert Ford (Chairman), Robert Ford (CEO), Robert Funck (CFO), Robert Funck, Jr. (EVP), Robert Funck, Jr. (EVP), Stephen Fussell (EVP), John Ginascol (EVP), Sammy Karam (SVP), Michelle Kumbier (Director), Andrew Lane (EVP), Joseph Manning (SVP), John Mccoy Jr. (VP), Nancy Mckinstry (Director), Mary Moreland (EVP), Louis Morrone (SVP), Phebe Novakovic (Director), Michael Pederson (SVP), Daniel Salvadori (EVP), Christopher Scoggins (SVP), Daniel Starks (Director), Julie Tyler (SVP), Andrea Wainer (EVP), Jared Watkin (SVP), Miles White (Chairman), Randel Woodgrift (SVP), and Brian Yoor (CFO). Learn More on Abbott Laboratories' active insiders.

Are insiders buying or selling shares of Abbott Laboratories?

During the last year, insiders at the healthcare product maker sold shares 8 times. They sold a total of 231,090 shares worth more than $26,431,118.59. The most recent insider tranaction occured on September, 12th when CEO Robert B Ford sold 141,679 shares worth more than $16,492,852.39. Insiders at Abbott Laboratories own 1.1% of the company. Learn More about insider trades at Abbott Laboratories.

Information on this page was last updated on 9/12/2024.

Daniel J. Starks Insider Trading History at Abbott Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/26/2023Sell50,000$94.05$4,702,500.006,725,316View SEC Filing Icon  
7/27/2023Sell50,000$113.76$5,688,000.006,775,316View SEC Filing Icon  
5/2/2023Sell50,000$111.02$5,551,000.006,825,316View SEC Filing Icon  
10/27/2022Sell50,000$97.46$4,873,000.006,873,500View SEC Filing Icon  
7/26/2022Sell50,000$109.14$5,457,000.006,923,500View SEC Filing Icon  
5/3/2022Sell50,000$113.22$5,661,000.006,973,500View SEC Filing Icon  
2/27/2018Buy40,037$60.67$2,429,044.796,943,348View SEC Filing Icon  
See Full Table

Daniel J. Starks Buying and Selling Activity at Abbott Laboratories

This chart shows Daniel J Starks's buying and selling at Abbott Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Abbott Laboratories Company Overview

Abbott Laboratories logo
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $114.31
Low: $112.96
High: $114.51

50 Day Range

MA: $116.04
Low: $111.93
High: $119.39

2 Week Range

Now: $114.31
Low: $99.71
High: $121.64

Volume

4,027,341 shs

Average Volume

5,649,993 shs

Market Capitalization

$198.27 billion

P/E Ratio

34.74

Dividend Yield

1.96%

Beta

0.73